Accounting There is on-going monitoring and evaluation of the project activity within each of the eight HEIs in the partnership. A Steering Group, whose membership includes a representative of each of the partner institutions regulates and controls the project activity. The Higher Education Authority, as the funding organisation on behalf of the Department of Education and Skills is responsible for the overall project monitoring and evaluation. The integration strand of the REAP project supports HEI mainstreaming, transfer and wider dissemination of the EmployerHEI framework established in the implementation strand of REAP through networking and collaboration with education and employer-led organisations ensuring integration with complementary programmes and initiatives.

Question 111 What is the maintenance dose of phenytoin in seizures arising as a complication of chronic renal failure?

Question 112 I know that the loading dose of phenytoin in status epilepticus is 20 mg/kg with an upper limit of 1000 mg but if the same situation arose as a complication of chronic renal failure (on regular dialysis), should this dose remain the same or be reduced? If reduced, what should the dose be?

Question 113 1. What is the most effective antiepileptic for a patient with simple partial motor status epilepticus who is not responding to a loading dose of phenytoin? 2. How long does phenytoin, given in a loading dose, take to work?

Question 114 Is valproate effective if given rectally in status epilepticus and, if so, what dose is recommended?

Question 115 In simple partial motor status epilepticus, if the patient does not respond to diazepam and phenytoin, is it justifiable to proceed to anaesthetic medication?

Question 116 What is the recommended upper limit dose of lamotrigine when combined with both carbamazepine and valproate?

Question 117 Is a valproate-lamotrigine combination more effective than carbamazepine on its own against partial seizures?

Question 118 Why is the incidence of parkinsonism less common in smokers?

Question 119 Is it recommended to start the treatment of parkinsonism with dopamine agonists alone in elderly (over 60 years old) patients, and to delay using L-dopa until the disease has progressed much further? Is there a rationale for this protocol in younger patients?

Question 120 Does amantadine increase the endogenous release of dopamine, thus aiding early treatment of parkinsonism?